Preventing memory loss in Parkinson's with a GBA gene mutation
Part of Brain & nervous system clinical trials.
This study tests if a drug called prasinezumab can help prevent memory and thinking problems in people with Parkinson's disease who have a specific change in their GBA gene. It looks at whether the treatment can slow down cognitive decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of Parkinson's disease.
- You have a specific, known serious change in your GBA gene (your doctor can check this).
- You are between 35 and 80 years old.
- Your memory and thinking are still fairly good (a score of 21 or more on a thinking test).
- You are able to walk without too much trouble when your Parkinson's medication is working.
- You are not planning to have deep brain stimulation surgery (or similar) in the next 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called prasinezumab, given through a vein (IV), to see if it can slow the progression of early-stage Parkinson's disease. It is for people who are on only one Parkinson's medication and have not yet developed motor complications.
This study looks at people with Parkinson’s who carry a specific genetic change in the GBA gene. It uses several tests (including brain scans) to understand the disease better and may help guide future treatments.
This study looks at non-motor symptoms (like mood, thinking, or sleep problems) in people with a specific genetic change linked to Parkinson's disease. It compares those with the GBA gene change to those without it to see how symptoms differ.
This trial tests a gene therapy product called VGN-R08b for people with Parkinson's disease who have a specific genetic change (GBA1 mutation). The goal is to help improve movement and daily function.
This study looks at early (before full disease) Parkinson-like symptoms in people who carry a specific genetic change called GBA1. It may help researchers understand who could develop Parkinson’s and how early signs can be tracked.
This study tests a new gene therapy called LY-N001, which is injected directly into the brain. It is for people with moderate to advanced Parkinson's disease who have a specific genetic change in the GBA1 gene. The goal is to see if this treatment is safe and can help improve symptoms.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.